Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from Southwest Oncology Group randomized trials

Journal of Clinical Oncology

Volumn 26, Issue 3, 2008, Pages 463-467

  Lara Jr , Primo N ^a   Redman, Mary W ^a   Kelly, Karen ^a   Edelman, Martin J ^a   Williamson, Stephen K ^a   Crowley, John J ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM; TIRAPAZAMINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CONTROL GROUPS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38649094549     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.0344     Document Type: Article

References (15)

1. Therasse P: Measuring the clinical response: What does it mean? Eur J Cancer 38:1817-1823, 2002
2. Gatzemeier U, von Pawel J, Gottfried M, et al: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390-3399, 2000
3. Klastersky J, Sculier JPO, Laccroiz H, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer. J Clin Oncol 8:1556-1562, 1990
4. Gandara DR, Crowley J, Livingston R, et al: Evaluation of cisplatin intensity in metastatic nonsmall-cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 11:873-878, 1993
5. Weiss GB, Bunce H III, Hokanson JA: Comparing survival of responders and non-responders after treatment: A potential source of confusion in interpreting cancer clinical trials. Controlled Clin Trials 4:43-52, 1983
6. Zubrod CG, Schneiderman M, Frei E III, et al: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 11:7-33, 1960
7. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
8. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 10:259-253, 1992
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
10. Erasmus JJ, Gladish GW, Broemeling L, et al: Interobserver and intraobserver variability in measurement of non-small cell lung cancer lesions: Implications for assessment of tumor response. J Clin Oncol 21:2574-2582, 2003
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in lung cancer. N Engl J Med 353: 1739-1741, 2005
12. Kelly K, Crowley J, Bunn P, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
13. Edelman M, Clark JI, Chanski K, et al: Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10:5022-5026, 2004
14. Williamson SK, Crowley J, Lara PN, et al: Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group trial S0003. J Clin Oncol 23:9097-9104, 2005
15. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983